| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dry Eye Syndromes | 115 | 2023 | 386 | 30.360 |
Why?
|
| Corneal Transplantation | 82 | 2024 | 386 | 21.610 |
Why?
|
| Cornea | 142 | 2024 | 1524 | 17.950 |
Why?
|
| Corneal Neovascularization | 46 | 2022 | 188 | 10.110 |
Why?
|
| Corneal Diseases | 39 | 2024 | 636 | 9.250 |
Why?
|
| Keratitis | 26 | 2024 | 268 | 6.870 |
Why?
|
| Graft Survival | 52 | 2021 | 3737 | 6.140 |
Why?
|
| Graft vs Host Disease | 27 | 2023 | 2957 | 5.340 |
Why?
|
| Graft Rejection | 48 | 2022 | 4397 | 5.140 |
Why?
|
| Epithelium, Corneal | 22 | 2020 | 247 | 5.120 |
Why?
|
| Tears | 35 | 2023 | 256 | 4.870 |
Why?
|
| Lymphangiogenesis | 27 | 2021 | 172 | 4.800 |
Why?
|
| Th17 Cells | 15 | 2022 | 766 | 4.600 |
Why?
|
| Conjunctiva | 30 | 2022 | 494 | 4.080 |
Why?
|
| Corneal Ulcer | 10 | 2023 | 169 | 4.010 |
Why?
|
| alpha-MSH | 6 | 2024 | 68 | 3.790 |
Why?
|
| Mice, Inbred BALB C | 87 | 2023 | 6386 | 3.780 |
Why?
|
| Endothelium, Corneal | 17 | 2023 | 199 | 3.550 |
Why?
|
| Corneal Dystrophies, Hereditary | 7 | 2022 | 81 | 3.460 |
Why?
|
| Trigeminal Nerve Diseases | 6 | 2022 | 55 | 3.270 |
Why?
|
| Microscopy, Confocal | 35 | 2023 | 1970 | 3.270 |
Why?
|
| T-Lymphocytes, Regulatory | 20 | 2022 | 2988 | 3.260 |
Why?
|
| Antigen-Presenting Cells | 21 | 2023 | 973 | 3.250 |
Why?
|
| Corneal Perforation | 5 | 2022 | 32 | 3.210 |
Why?
|
| Keratoplasty, Penetrating | 22 | 2019 | 155 | 3.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 17 | 2021 | 118 | 2.970 |
Why?
|
| Ophthalmic Nerve | 12 | 2017 | 43 | 2.850 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 4 | 2023 | 109 | 2.830 |
Why?
|
| Disease Models, Animal | 62 | 2022 | 18029 | 2.790 |
Why?
|
| Conjunctivitis | 6 | 2021 | 158 | 2.670 |
Why?
|
| Dendritic Cells | 28 | 2020 | 2725 | 2.640 |
Why?
|
| Mice, Inbred C57BL | 104 | 2022 | 21827 | 2.580 |
Why?
|
| Fluorescein | 12 | 2022 | 171 | 2.510 |
Why?
|
| Eye Diseases | 9 | 2021 | 669 | 2.470 |
Why?
|
| Keratitis, Herpetic | 8 | 2022 | 81 | 2.420 |
Why?
|
| Ophthalmic Solutions | 24 | 2021 | 317 | 2.390 |
Why?
|
| Limbus Corneae | 10 | 2021 | 144 | 2.350 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 7 | 2019 | 245 | 2.330 |
Why?
|
| Sickness Impact Profile | 6 | 2020 | 302 | 2.320 |
Why?
|
| Angiogenesis Inhibitors | 19 | 2022 | 2038 | 2.290 |
Why?
|
| Autoimmunity | 11 | 2021 | 1349 | 2.260 |
Why?
|
| Lymphatic Vessels | 15 | 2017 | 353 | 2.260 |
Why?
|
| Cataract | 9 | 2023 | 834 | 2.240 |
Why?
|
| Meibomian Glands | 21 | 2022 | 85 | 2.210 |
Why?
|
| Lacrimal Apparatus | 12 | 2022 | 225 | 2.160 |
Why?
|
| Corneal Edema | 4 | 2023 | 52 | 2.150 |
Why?
|
| Mice | 158 | 2024 | 81183 | 2.030 |
Why?
|
| Conjunctival Diseases | 7 | 2020 | 122 | 1.960 |
Why?
|
| Animals | 213 | 2024 | 168757 | 1.930 |
Why?
|
| Autoimmune Diseases | 14 | 2022 | 2133 | 1.860 |
Why?
|
| Vascular Endothelial Growth Factor C | 13 | 2017 | 126 | 1.840 |
Why?
|
| Receptors, Neurokinin-1 | 5 | 2022 | 129 | 1.820 |
Why?
|
| Tissue Adhesives | 5 | 2021 | 179 | 1.810 |
Why?
|
| Eye | 15 | 2021 | 729 | 1.810 |
Why?
|
| Visual Acuity | 28 | 2021 | 2530 | 1.750 |
Why?
|
| Transplantation, Homologous | 41 | 2022 | 4776 | 1.720 |
Why?
|
| Substance P | 5 | 2022 | 335 | 1.700 |
Why?
|
| Keratoconjunctivitis Sicca | 6 | 2021 | 27 | 1.680 |
Why?
|
| Thrombospondin 1 | 5 | 2019 | 250 | 1.660 |
Why?
|
| Fluorophotometry | 13 | 2021 | 40 | 1.620 |
Why?
|
| Receptors, CCR7 | 5 | 2016 | 108 | 1.560 |
Why?
|
| Interferon-gamma | 16 | 2024 | 3206 | 1.520 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 21 | 2017 | 428 | 1.490 |
Why?
|
| Endothelial Cells | 13 | 2023 | 3479 | 1.490 |
Why?
|
| Hypersensitivity, Delayed | 14 | 2013 | 484 | 1.470 |
Why?
|
| Hyperemia | 2 | 2021 | 225 | 1.420 |
Why?
|
| Artificial Organs | 4 | 2016 | 204 | 1.420 |
Why?
|
| Interleukin-17 | 7 | 2022 | 899 | 1.400 |
Why?
|
| Corneal Stroma | 12 | 2015 | 174 | 1.390 |
Why?
|
| Administration, Topical | 21 | 2016 | 690 | 1.370 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 14 | 2016 | 297 | 1.350 |
Why?
|
| Immune Tolerance | 11 | 2018 | 2258 | 1.310 |
Why?
|
| Interleukin-2 | 7 | 2020 | 1904 | 1.310 |
Why?
|
| Hydrogels | 4 | 2021 | 724 | 1.300 |
Why?
|
| Tissue Donors | 10 | 2020 | 2240 | 1.280 |
Why?
|
| Anti-Inflammatory Agents | 11 | 2021 | 1790 | 1.270 |
Why?
|
| Cranial Nerve Diseases | 7 | 2017 | 112 | 1.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 21 | 2022 | 3508 | 1.220 |
Why?
|
| Eye Infections, Fungal | 3 | 2017 | 110 | 1.220 |
Why?
|
| Flow Cytometry | 27 | 2018 | 5974 | 1.190 |
Why?
|
| Neovascularization, Pathologic | 12 | 2021 | 2635 | 1.170 |
Why?
|
| Immunosuppressive Agents | 14 | 2018 | 4149 | 1.160 |
Why?
|
| Chemotaxis, Leukocyte | 6 | 2019 | 675 | 1.150 |
Why?
|
| Receptors, Chemokine | 8 | 2023 | 669 | 1.150 |
Why?
|
| Eye Proteins | 9 | 2021 | 646 | 1.140 |
Why?
|
| Sialoglycoproteins | 10 | 2005 | 318 | 1.120 |
Why?
|
| Chemokine CCL21 | 3 | 2016 | 51 | 1.110 |
Why?
|
| Corneal Endothelial Cell Loss | 2 | 2017 | 24 | 1.100 |
Why?
|
| Acanthamoeba Keratitis | 3 | 2018 | 17 | 1.100 |
Why?
|
| Adaptive Immunity | 5 | 2018 | 713 | 1.080 |
Why?
|
| Immunologic Memory | 4 | 2020 | 1348 | 1.070 |
Why?
|
| Male | 184 | 2024 | 350118 | 1.070 |
Why?
|
| Corneal Opacity | 5 | 2019 | 60 | 1.070 |
Why?
|
| Serpins | 4 | 2021 | 247 | 1.070 |
Why?
|
| Neovascularization, Physiologic | 10 | 2020 | 1351 | 1.070 |
Why?
|
| Cell Movement | 18 | 2018 | 5217 | 1.060 |
Why?
|
| Anti-Allergic Agents | 2 | 2018 | 141 | 1.030 |
Why?
|
| Adoptive Transfer | 5 | 2019 | 844 | 1.010 |
Why?
|
| Fluorescent Dyes | 5 | 2017 | 1917 | 0.990 |
Why?
|
| Immunity, Innate | 11 | 2023 | 2958 | 0.980 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 8 | 2017 | 546 | 0.970 |
Why?
|
| Inflammation | 19 | 2024 | 10638 | 0.970 |
Why?
|
| Melanocortins | 1 | 2024 | 11 | 0.970 |
Why?
|
| Nerve Growth Factors | 4 | 2021 | 574 | 0.970 |
Why?
|
| Humans | 253 | 2024 | 744343 | 0.970 |
Why?
|
| Cytokines | 22 | 2023 | 7322 | 0.960 |
Why?
|
| Interleukin-7 | 2 | 2016 | 142 | 0.960 |
Why?
|
| Fuchs' Endothelial Dystrophy | 2 | 2023 | 84 | 0.950 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 2 | 2023 | 123 | 0.950 |
Why?
|
| Conjunctivitis, Allergic | 2 | 2022 | 130 | 0.950 |
Why?
|
| Eye Pain | 3 | 2022 | 47 | 0.940 |
Why?
|
| Mustard Gas | 1 | 2023 | 16 | 0.930 |
Why?
|
| Female | 160 | 2024 | 380194 | 0.920 |
Why?
|
| Th1 Cells | 12 | 2022 | 1057 | 0.910 |
Why?
|
| Lymph Nodes | 16 | 2019 | 3474 | 0.910 |
Why?
|
| Lymphocyte Activation | 12 | 2019 | 5524 | 0.890 |
Why?
|
| Monocytes | 10 | 2023 | 2596 | 0.890 |
Why?
|
| Eye Infections, Viral | 2 | 2021 | 57 | 0.890 |
Why?
|
| Ophthalmology | 5 | 2020 | 508 | 0.880 |
Why?
|
| Eye Injuries | 7 | 2023 | 245 | 0.870 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2022 | 5442 | 0.870 |
Why?
|
| Langerhans Cells | 7 | 2007 | 173 | 0.860 |
Why?
|
| Interleukin-1beta | 10 | 2018 | 972 | 0.860 |
Why?
|
| Wound Healing | 11 | 2023 | 2785 | 0.850 |
Why?
|
| Aqueous Humor | 6 | 2019 | 161 | 0.820 |
Why?
|
| Tumor Necrosis Factor-alpha | 18 | 2023 | 4420 | 0.810 |
Why?
|
| Nerve Degeneration | 3 | 2016 | 748 | 0.810 |
Why?
|
| Gene Expression | 17 | 2022 | 7799 | 0.800 |
Why?
|
| Interleukin-23 | 2 | 2020 | 193 | 0.790 |
Why?
|
| Scopolamine | 4 | 2016 | 99 | 0.790 |
Why?
|
| Cyclosporine | 6 | 2018 | 786 | 0.790 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2022 | 140 | 0.780 |
Why?
|
| Immunity | 8 | 2016 | 1012 | 0.780 |
Why?
|
| Vision Disorders | 9 | 2023 | 1058 | 0.770 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2015 | 664 | 0.770 |
Why?
|
| RNA, Messenger | 28 | 2016 | 13033 | 0.770 |
Why?
|
| Vision, Ocular | 3 | 2020 | 464 | 0.770 |
Why?
|
| Prostheses and Implants | 4 | 2016 | 1387 | 0.770 |
Why?
|
| Cyanoacrylates | 3 | 2020 | 49 | 0.770 |
Why?
|
| Middle Aged | 101 | 2022 | 213383 | 0.760 |
Why?
|
| Receptors, Interleukin-1 | 8 | 2003 | 262 | 0.760 |
Why?
|
| Anterior Chamber | 5 | 2005 | 197 | 0.750 |
Why?
|
| Gene Expression Regulation | 11 | 2016 | 12072 | 0.750 |
Why?
|
| Burns, Chemical | 6 | 2021 | 159 | 0.750 |
Why?
|
| Leukocytes | 8 | 2019 | 2043 | 0.730 |
Why?
|
| Cell Count | 15 | 2019 | 1856 | 0.730 |
Why?
|
| Patients | 2 | 2017 | 900 | 0.720 |
Why?
|
| Janus Kinase 3 | 2 | 2017 | 78 | 0.710 |
Why?
|
| Purinergic Antagonists | 1 | 2019 | 11 | 0.710 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 16 | 2013 | 4751 | 0.700 |
Why?
|
| Transplantation Immunology | 4 | 2016 | 546 | 0.700 |
Why?
|
| Guaifenesin | 1 | 2019 | 5 | 0.700 |
Why?
|
| Aged | 74 | 2024 | 163280 | 0.700 |
Why?
|
| Glucocorticoids | 8 | 2018 | 2107 | 0.690 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 16 | 2018 | 3870 | 0.690 |
Why?
|
| Sjogren's Syndrome | 13 | 2018 | 233 | 0.680 |
Why?
|
| Interleukin-1 | 8 | 2007 | 1263 | 0.680 |
Why?
|
| Receptors, Purinergic | 1 | 2019 | 66 | 0.680 |
Why?
|
| Major Histocompatibility Complex | 8 | 2007 | 936 | 0.670 |
Why?
|
| Interleukin-10 | 3 | 2019 | 1200 | 0.670 |
Why?
|
| Denervation | 4 | 2013 | 278 | 0.650 |
Why?
|
| Glycoproteins | 12 | 2017 | 2263 | 0.650 |
Why?
|
| Environment, Controlled | 3 | 2009 | 46 | 0.650 |
Why?
|
| Nerve Growth Factor | 1 | 2019 | 149 | 0.650 |
Why?
|
| Glaucoma | 3 | 2018 | 1159 | 0.640 |
Why?
|
| T-Lymphocytes | 14 | 2021 | 10180 | 0.640 |
Why?
|
| Killer Cells, Natural | 4 | 2022 | 2133 | 0.630 |
Why?
|
| Organ Preservation | 2 | 2020 | 331 | 0.630 |
Why?
|
| Isoantigens | 10 | 2016 | 567 | 0.620 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2018 | 179 | 0.620 |
Why?
|
| CD40 Ligand | 4 | 2009 | 526 | 0.620 |
Why?
|
| Phacoemulsification | 2 | 2015 | 149 | 0.610 |
Why?
|
| Aging | 10 | 2022 | 8664 | 0.610 |
Why?
|
| Chemokines | 7 | 2012 | 970 | 0.610 |
Why?
|
| Membrane Transport Proteins | 11 | 2017 | 1028 | 0.600 |
Why?
|
| Optics and Photonics | 1 | 2019 | 321 | 0.600 |
Why?
|
| Electrocoagulation | 3 | 2021 | 158 | 0.600 |
Why?
|
| Adult | 78 | 2021 | 214055 | 0.590 |
Why?
|
| Histocompatibility Antigens Class II | 8 | 2010 | 1475 | 0.590 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 104 | 0.590 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2024 | 4386 | 0.590 |
Why?
|
| Disease Management | 5 | 2021 | 2459 | 0.580 |
Why?
|
| Methylprednisolone | 2 | 2016 | 387 | 0.580 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2023 | 1116 | 0.570 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 1782 | 0.570 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2018 | 1855 | 0.570 |
Why?
|
| Coculture Techniques | 8 | 2017 | 1341 | 0.570 |
Why?
|
| Signal Transduction | 15 | 2021 | 23403 | 0.570 |
Why?
|
| Phospholipase C gamma | 1 | 2016 | 128 | 0.570 |
Why?
|
| Posterior Eye Segment | 1 | 2016 | 14 | 0.560 |
Why?
|
| Chemokine CCL19 | 1 | 2016 | 35 | 0.560 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2016 | 39 | 0.560 |
Why?
|
| Drug Delivery Systems | 4 | 2021 | 2219 | 0.560 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2014 | 986 | 0.560 |
Why?
|
| Anti-Bacterial Agents | 8 | 2023 | 7181 | 0.560 |
Why?
|
| Docosahexaenoic Acids | 3 | 2019 | 875 | 0.550 |
Why?
|
| Scleritis | 1 | 2016 | 100 | 0.540 |
Why?
|
| Interleukin-15 | 1 | 2016 | 184 | 0.540 |
Why?
|
| Eyelids | 1 | 2018 | 265 | 0.540 |
Why?
|
| Membrane Glycoproteins | 5 | 2011 | 3768 | 0.530 |
Why?
|
| Retrospective Studies | 39 | 2023 | 77449 | 0.530 |
Why?
|
| Anterior Eye Segment | 4 | 2016 | 152 | 0.530 |
Why?
|
| Immunity, Cellular | 3 | 2016 | 1607 | 0.530 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 1660 | 0.520 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 57776 | 0.520 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 1620 | 0.520 |
Why?
|
| Cells, Cultured | 21 | 2020 | 19229 | 0.520 |
Why?
|
| Young Adult | 27 | 2021 | 56430 | 0.520 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2012 | 599 | 0.510 |
Why?
|
| Thyroid Diseases | 1 | 2018 | 379 | 0.510 |
Why?
|
| Quality of Life | 10 | 2022 | 12804 | 0.510 |
Why?
|
| Angiopoietin-1 | 1 | 2015 | 114 | 0.510 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2014 | 772 | 0.510 |
Why?
|
| Trigeminal Nerve | 2 | 2015 | 249 | 0.510 |
Why?
|
| Stem Cells | 5 | 2020 | 3567 | 0.500 |
Why?
|
| Tobramycin | 1 | 2014 | 69 | 0.500 |
Why?
|
| Chronic Disease | 12 | 2022 | 9146 | 0.500 |
Why?
|
| Transplantation, Isogeneic | 6 | 2017 | 257 | 0.500 |
Why?
|
| Body Size | 1 | 2017 | 461 | 0.490 |
Why?
|
| Ocular Hypertension | 1 | 2016 | 198 | 0.490 |
Why?
|
| Immunotherapy | 2 | 2020 | 4445 | 0.490 |
Why?
|
| Macrophages | 11 | 2023 | 5655 | 0.490 |
Why?
|
| Green Fluorescent Proteins | 2 | 2019 | 2088 | 0.490 |
Why?
|
| Fibrillar Collagens | 1 | 2014 | 41 | 0.480 |
Why?
|
| Immunity, Mucosal | 1 | 2017 | 490 | 0.480 |
Why?
|
| Elastic Tissue | 1 | 2014 | 65 | 0.480 |
Why?
|
| Mucous Membrane | 1 | 2017 | 673 | 0.480 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2016 | 547 | 0.470 |
Why?
|
| E-Selectin | 1 | 2016 | 579 | 0.460 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 494 | 0.460 |
Why?
|
| Receptors, CCR5 | 2 | 2006 | 497 | 0.450 |
Why?
|
| Chemokine CCL20 | 1 | 2013 | 64 | 0.450 |
Why?
|
| Peptides | 4 | 2011 | 4409 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 8 | 2015 | 9274 | 0.450 |
Why?
|
| Cell Proliferation | 10 | 2017 | 10481 | 0.450 |
Why?
|
| Receptors, CCR6 | 1 | 2013 | 81 | 0.440 |
Why?
|
| Health Surveys | 3 | 2020 | 4037 | 0.440 |
Why?
|
| Androstadienes | 1 | 2014 | 346 | 0.440 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2015 | 192 | 0.440 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 2025 | 0.430 |
Why?
|
| Follow-Up Studies | 23 | 2021 | 39050 | 0.430 |
Why?
|
| Epithelial Cells | 10 | 2023 | 3690 | 0.430 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2017 | 552 | 0.430 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 11366 | 0.420 |
Why?
|
| Muscarinic Antagonists | 1 | 2013 | 137 | 0.420 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2012 | 33 | 0.420 |
Why?
|
| Optic Nerve Diseases | 1 | 2016 | 327 | 0.420 |
Why?
|
| Blood Vessels | 4 | 2017 | 1125 | 0.420 |
Why?
|
| Tacrolimus | 1 | 2016 | 743 | 0.420 |
Why?
|
| Antibodies, Neutralizing | 5 | 2024 | 1978 | 0.420 |
Why?
|
| Cross-Sectional Studies | 24 | 2023 | 25043 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor D | 5 | 2015 | 63 | 0.420 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 455 | 0.420 |
Why?
|
| Apoptosis | 9 | 2020 | 9727 | 0.420 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2019 | 349 | 0.410 |
Why?
|
| Prospective Studies | 28 | 2022 | 53288 | 0.410 |
Why?
|
| bcl-X Protein | 2 | 2011 | 411 | 0.410 |
Why?
|
| Retinal Diseases | 5 | 2019 | 683 | 0.410 |
Why?
|
| Catechin | 1 | 2011 | 66 | 0.410 |
Why?
|
| Eye Infections | 3 | 2015 | 64 | 0.400 |
Why?
|
| Nanoparticles | 2 | 2021 | 1905 | 0.400 |
Why?
|
| Pain Measurement | 3 | 2017 | 3420 | 0.400 |
Why?
|
| Antigens, CD | 9 | 2013 | 4026 | 0.400 |
Why?
|
| Immunization | 3 | 2001 | 1256 | 0.400 |
Why?
|
| Uveitis | 4 | 2019 | 375 | 0.400 |
Why?
|
| Polychondritis, Relapsing | 1 | 2011 | 28 | 0.400 |
Why?
|
| Bioprosthesis | 1 | 2016 | 596 | 0.400 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 2014 | 517 | 0.400 |
Why?
|
| Intraocular Pressure | 7 | 2016 | 1270 | 0.390 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 1741 | 0.390 |
Why?
|
| Forkhead Transcription Factors | 4 | 2016 | 1613 | 0.390 |
Why?
|
| Eyelid Diseases | 6 | 2020 | 155 | 0.390 |
Why?
|
| Pyrimidines | 2 | 2014 | 2942 | 0.390 |
Why?
|
| Double-Blind Method | 11 | 2019 | 12026 | 0.380 |
Why?
|
| Mesenchymal Stem Cells | 6 | 2021 | 1632 | 0.380 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2006 | 595 | 0.380 |
Why?
|
| Receptors, CCR2 | 2 | 2009 | 212 | 0.380 |
Why?
|
| Bone Marrow Cells | 8 | 2014 | 2513 | 0.380 |
Why?
|
| Choroidal Neovascularization | 1 | 2014 | 343 | 0.380 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2016 | 1838 | 0.380 |
Why?
|
| Lymphatic System | 5 | 2009 | 253 | 0.370 |
Why?
|
| Descemet Membrane | 2 | 2022 | 73 | 0.370 |
Why?
|
| Leadership | 1 | 2020 | 1357 | 0.370 |
Why?
|
| Mice, Knockout | 15 | 2021 | 14557 | 0.370 |
Why?
|
| Immune System | 7 | 2011 | 805 | 0.370 |
Why?
|
| Severity of Illness Index | 10 | 2018 | 15540 | 0.360 |
Why?
|
| Xerophthalmia | 1 | 2009 | 18 | 0.360 |
Why?
|
| Bone Marrow Transplantation | 2 | 2013 | 2765 | 0.360 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2015 | 3772 | 0.360 |
Why?
|
| Contact Lenses | 5 | 2020 | 145 | 0.360 |
Why?
|
| Cell Adhesion Molecules | 2 | 2011 | 1602 | 0.360 |
Why?
|
| Retina | 5 | 2018 | 2616 | 0.360 |
Why?
|
| Chemokine CCL5 | 4 | 2007 | 209 | 0.360 |
Why?
|
| Azithromycin | 1 | 2011 | 196 | 0.350 |
Why?
|
| Lymphocyte Count | 3 | 2019 | 793 | 0.350 |
Why?
|
| Models, Animal | 7 | 2020 | 2171 | 0.350 |
Why?
|
| Prevalence | 11 | 2022 | 15226 | 0.350 |
Why?
|
| Androgens | 7 | 2003 | 1281 | 0.350 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2012 | 560 | 0.350 |
Why?
|
| Oxidative Stress | 1 | 2020 | 3086 | 0.340 |
Why?
|
| Mice, Inbred C3H | 5 | 2016 | 964 | 0.340 |
Why?
|
| Internet | 2 | 2021 | 3064 | 0.340 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 565 | 0.330 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1637 | 0.330 |
Why?
|
| Electrolysis | 3 | 2013 | 9 | 0.330 |
Why?
|
| Homeostasis | 4 | 2017 | 3340 | 0.330 |
Why?
|
| Cell Differentiation | 10 | 2020 | 11483 | 0.330 |
Why?
|
| Cataract Extraction | 2 | 2004 | 481 | 0.330 |
Why?
|
| Integrin alpha4beta1 | 1 | 2008 | 121 | 0.330 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 1432 | 0.320 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2016 | 282 | 0.320 |
Why?
|
| Contrast Sensitivity | 2 | 2019 | 244 | 0.320 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 719 | 0.310 |
Why?
|
| Tropicamide | 1 | 2007 | 23 | 0.310 |
Why?
|
| Integrin alpha1beta1 | 1 | 2007 | 8 | 0.310 |
Why?
|
| Treatment Outcome | 18 | 2021 | 63114 | 0.310 |
Why?
|
| Growth Inhibitors | 1 | 2009 | 385 | 0.300 |
Why?
|
| Eye Burns | 3 | 2017 | 103 | 0.300 |
Why?
|
| Risk Factors | 30 | 2021 | 72290 | 0.300 |
Why?
|
| alpha-Linolenic Acid | 1 | 2008 | 144 | 0.300 |
Why?
|
| Macrophage Inflammatory Proteins | 3 | 2005 | 122 | 0.300 |
Why?
|
| Pyrroles | 1 | 2014 | 1146 | 0.300 |
Why?
|
| Mydriatics | 1 | 2007 | 68 | 0.300 |
Why?
|
| Rabbits | 11 | 2021 | 4894 | 0.290 |
Why?
|
| Linoleic Acid | 1 | 2008 | 157 | 0.290 |
Why?
|
| Lymphocyte Depletion | 1 | 2009 | 608 | 0.290 |
Why?
|
| RNA | 4 | 2016 | 2749 | 0.290 |
Why?
|
| Transplantation Tolerance | 1 | 2012 | 617 | 0.290 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2007 | 139 | 0.280 |
Why?
|
| Uveitis, Anterior | 2 | 2017 | 101 | 0.280 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2019 | 582 | 0.280 |
Why?
|
| Streptozocin | 2 | 2024 | 196 | 0.280 |
Why?
|
| Pupil | 1 | 2007 | 149 | 0.280 |
Why?
|
| Epithelium | 4 | 2018 | 1679 | 0.280 |
Why?
|
| Immunophenotyping | 5 | 2018 | 1880 | 0.280 |
Why?
|
| Lipoxins | 1 | 2009 | 412 | 0.280 |
Why?
|
| Eye Neoplasms | 2 | 2005 | 313 | 0.280 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 3798 | 0.280 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 612 | 0.270 |
Why?
|
| Microglia | 3 | 2019 | 1266 | 0.270 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 1114 | 0.270 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2005 | 50 | 0.270 |
Why?
|
| Phosphoproteins | 2 | 2012 | 2440 | 0.260 |
Why?
|
| Piperidines | 1 | 2014 | 1602 | 0.260 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 528 | 0.260 |
Why?
|
| Tomography, Optical Coherence | 4 | 2019 | 2657 | 0.260 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1403 | 0.260 |
Why?
|
| Adhesives | 2 | 2021 | 61 | 0.250 |
Why?
|
| Receptors, Melanocortin | 1 | 2024 | 25 | 0.240 |
Why?
|
| Time Factors | 11 | 2021 | 40075 | 0.240 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2011 | 1155 | 0.240 |
Why?
|
| Cell Survival | 4 | 2020 | 5882 | 0.240 |
Why?
|
| Mouth Mucosa | 2 | 2020 | 434 | 0.240 |
Why?
|
| Fibroblasts | 3 | 2014 | 4161 | 0.240 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 4665 | 0.240 |
Why?
|
| Microscopy, Fluorescence | 6 | 2012 | 2699 | 0.240 |
Why?
|
| Mechlorethamine | 1 | 2023 | 136 | 0.230 |
Why?
|
| Endothelium, Vascular | 2 | 2011 | 4456 | 0.230 |
Why?
|
| Herpes Zoster Ophthalmicus | 2 | 2015 | 36 | 0.230 |
Why?
|
| Antigenic Variation | 1 | 2004 | 125 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2013 | 1580 | 0.230 |
Why?
|
| Antioxidants | 1 | 2011 | 1663 | 0.230 |
Why?
|
| Eye Infections, Bacterial | 3 | 2015 | 235 | 0.230 |
Why?
|
| Viral Proteins | 1 | 2011 | 1900 | 0.230 |
Why?
|
| Staining and Labeling | 3 | 2018 | 1100 | 0.230 |
Why?
|
| Sulfonamides | 1 | 2013 | 1938 | 0.220 |
Why?
|
| Neuroglia | 2 | 2018 | 927 | 0.220 |
Why?
|
| Blindness | 4 | 2018 | 617 | 0.220 |
Why?
|
| Oligopeptides | 1 | 2008 | 1189 | 0.220 |
Why?
|
| Immunomodulation | 2 | 2018 | 541 | 0.220 |
Why?
|
| Tissue Preservation | 1 | 2023 | 182 | 0.220 |
Why?
|
| Cytoprotection | 1 | 2023 | 210 | 0.220 |
Why?
|
| Biological Availability | 2 | 2021 | 397 | 0.220 |
Why?
|
| Swine | 3 | 2021 | 5917 | 0.220 |
Why?
|
| Disability Evaluation | 3 | 2017 | 1827 | 0.210 |
Why?
|
| Case-Control Studies | 10 | 2023 | 21746 | 0.210 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 2001 | 65 | 0.210 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 2421 | 0.210 |
Why?
|
| Ovalbumin | 6 | 2015 | 719 | 0.210 |
Why?
|
| In Situ Nick-End Labeling | 4 | 2014 | 643 | 0.210 |
Why?
|
| Consensus | 6 | 2022 | 2959 | 0.210 |
Why?
|
| Photochemotherapy | 2 | 2017 | 807 | 0.210 |
Why?
|
| Pilot Projects | 4 | 2019 | 8324 | 0.210 |
Why?
|
| Trans-Activators | 1 | 2012 | 2924 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 5 | 2012 | 1799 | 0.200 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2021 | 76 | 0.200 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2019 | 110 | 0.200 |
Why?
|
| Blotting, Western | 6 | 2017 | 5179 | 0.200 |
Why?
|
| Antirheumatic Agents | 3 | 2016 | 1339 | 0.200 |
Why?
|
| Ligands | 3 | 2016 | 3282 | 0.200 |
Why?
|
| Incidence | 9 | 2020 | 20947 | 0.200 |
Why?
|
| Eye Banks | 2 | 2020 | 38 | 0.200 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 853 | 0.200 |
Why?
|
| Blinking | 2 | 2012 | 138 | 0.190 |
Why?
|
| Eye Injuries, Penetrating | 3 | 2004 | 115 | 0.190 |
Why?
|
| Adolescent | 18 | 2021 | 85781 | 0.190 |
Why?
|
| Silicone Elastomers | 1 | 2001 | 84 | 0.190 |
Why?
|
| Neutrophil Infiltration | 1 | 2023 | 390 | 0.190 |
Why?
|
| Sex Distribution | 4 | 2019 | 2297 | 0.190 |
Why?
|
| Conjunctivitis, Viral | 1 | 2020 | 6 | 0.190 |
Why?
|
| Cicatrix | 1 | 2007 | 764 | 0.190 |
Why?
|
| Massachusetts | 3 | 2021 | 8663 | 0.190 |
Why?
|
| Histamine | 1 | 2022 | 507 | 0.190 |
Why?
|
| Tensile Strength | 1 | 2021 | 335 | 0.190 |
Why?
|
| Guinea Pigs | 1 | 2022 | 1386 | 0.190 |
Why?
|
| Drug Implants | 3 | 2012 | 244 | 0.190 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5319 | 0.190 |
Why?
|
| Telemedicine | 1 | 2018 | 2872 | 0.190 |
Why?
|
| Eye Abnormalities | 2 | 2016 | 246 | 0.180 |
Why?
|
| Interleukin-8 | 1 | 2023 | 690 | 0.180 |
Why?
|
| Cell Line, Transformed | 1 | 2021 | 898 | 0.180 |
Why?
|
| Cell Line | 4 | 2023 | 15997 | 0.180 |
Why?
|
| Administration, Oral | 2 | 2019 | 3913 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 992 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2024 | 5535 | 0.180 |
Why?
|
| Interleukin-1alpha | 2 | 2011 | 84 | 0.180 |
Why?
|
| Adenoviridae | 1 | 2004 | 1099 | 0.180 |
Why?
|
| Recombinant Proteins | 6 | 2019 | 6622 | 0.180 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2017 | 264 | 0.180 |
Why?
|
| Gene Deletion | 2 | 2007 | 2751 | 0.180 |
Why?
|
| Expectorants | 1 | 2019 | 16 | 0.170 |
Why?
|
| Sutures | 2 | 2007 | 299 | 0.170 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2020 | 270 | 0.170 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 137 | 0.170 |
Why?
|
| Feasibility Studies | 4 | 2023 | 5078 | 0.170 |
Why?
|
| Phenotype | 6 | 2021 | 16365 | 0.170 |
Why?
|
| Observer Variation | 2 | 2017 | 2593 | 0.170 |
Why?
|
| Blood Group Incompatibility | 1 | 2000 | 146 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 11725 | 0.170 |
Why?
|
| Androgen-Insensitivity Syndrome | 3 | 2003 | 31 | 0.170 |
Why?
|
| Interleukin-12 | 2 | 2017 | 579 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2023 | 3200 | 0.170 |
Why?
|
| Hypertension | 2 | 2018 | 8480 | 0.170 |
Why?
|
| Species Specificity | 2 | 2017 | 2478 | 0.160 |
Why?
|
| Th2 Cells | 4 | 2013 | 1061 | 0.160 |
Why?
|
| Antibodies, Blocking | 2 | 2009 | 253 | 0.160 |
Why?
|
| Up-Regulation | 4 | 2015 | 4217 | 0.160 |
Why?
|
| Antibodies | 2 | 2007 | 2460 | 0.160 |
Why?
|
| Ciprofloxacin | 1 | 2020 | 315 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2005 | 1533 | 0.160 |
Why?
|
| Emulsions | 1 | 2018 | 156 | 0.160 |
Why?
|
| Disease Progression | 6 | 2020 | 13284 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2014 | 2282 | 0.160 |
Why?
|
| Organ Culture Techniques | 1 | 2020 | 813 | 0.160 |
Why?
|
| Cell Death | 1 | 2024 | 1706 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1180 | 0.160 |
Why?
|
| Linseed Oil | 1 | 2017 | 5 | 0.160 |
Why?
|
| Age Distribution | 3 | 2019 | 2902 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2013 | 3309 | 0.150 |
Why?
|
| Goblet Cells | 3 | 2007 | 287 | 0.150 |
Why?
|
| Postoperative Complications | 7 | 2023 | 15295 | 0.150 |
Why?
|
| Transplantation, Heterotopic | 1 | 2018 | 175 | 0.150 |
Why?
|
| Physicians | 2 | 2013 | 4567 | 0.150 |
Why?
|
| Prosthesis Design | 2 | 2014 | 2110 | 0.150 |
Why?
|
| Exophiala | 1 | 2017 | 2 | 0.150 |
Why?
|
| Eosinophils | 1 | 2022 | 955 | 0.150 |
Why?
|
| Virulence | 1 | 2021 | 1333 | 0.150 |
Why?
|
| Diathermy | 1 | 2017 | 18 | 0.150 |
Why?
|
| Optic Nerve Injuries | 1 | 2018 | 150 | 0.150 |
Why?
|
| Steroids | 3 | 2016 | 930 | 0.150 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2016 | 16 | 0.150 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 38 | 0.150 |
Why?
|
| Lectins, C-Type | 2 | 2011 | 588 | 0.140 |
Why?
|
| Cyclosporins | 1 | 2016 | 220 | 0.140 |
Why?
|
| Laser Therapy | 1 | 2004 | 1072 | 0.140 |
Why?
|
| Receptors, CCR1 | 2 | 2007 | 33 | 0.140 |
Why?
|
| Axons | 2 | 2016 | 1684 | 0.140 |
Why?
|
| Oxidation-Reduction | 2 | 2019 | 2187 | 0.140 |
Why?
|
| Leukocyte Elastase | 1 | 2017 | 113 | 0.140 |
Why?
|
| STAT5 Transcription Factor | 1 | 2016 | 259 | 0.140 |
Why?
|
| Serum | 1 | 2017 | 214 | 0.140 |
Why?
|
| Transfection | 1 | 2004 | 5892 | 0.140 |
Why?
|
| Lipid Metabolism | 6 | 2006 | 1889 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 1519 | 0.140 |
Why?
|
| Doxycycline | 1 | 2017 | 326 | 0.130 |
Why?
|
| Dacryocystitis | 1 | 2016 | 70 | 0.130 |
Why?
|
| Morbidity | 1 | 2021 | 1769 | 0.130 |
Why?
|
| Nasolacrimal Duct | 1 | 2016 | 74 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 6489 | 0.130 |
Why?
|
| Humidity | 2 | 2007 | 197 | 0.130 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 492 | 0.130 |
Why?
|
| Tonometry, Ocular | 1 | 2016 | 237 | 0.130 |
Why?
|
| Keratotomy, Radial | 1 | 1994 | 5 | 0.130 |
Why?
|
| United States | 13 | 2022 | 69872 | 0.130 |
Why?
|
| Mice, Inbred Strains | 4 | 2002 | 1827 | 0.130 |
Why?
|
| Mucins | 3 | 2021 | 564 | 0.130 |
Why?
|
| Polymers | 2 | 2021 | 1621 | 0.130 |
Why?
|
| Keratoconjunctivitis | 1 | 2015 | 53 | 0.130 |
Why?
|
| Keratoconus | 2 | 2017 | 121 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2001 | 1203 | 0.130 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 4933 | 0.130 |
Why?
|
| Indazoles | 2 | 2015 | 289 | 0.130 |
Why?
|
| Pseudophakia | 1 | 2015 | 62 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 2 | 2014 | 425 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 2 | 2016 | 2007 | 0.120 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 310 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 638 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2004 | 3420 | 0.120 |
Why?
|
| Miniaturization | 1 | 2014 | 164 | 0.120 |
Why?
|
| Retinal Degeneration | 1 | 2018 | 415 | 0.120 |
Why?
|
| Osmolar Concentration | 2 | 2013 | 683 | 0.120 |
Why?
|
| Leprosy | 1 | 1994 | 124 | 0.120 |
Why?
|
| Chemokine CXCL10 | 2 | 2008 | 304 | 0.120 |
Why?
|
| Lubricants | 1 | 2013 | 31 | 0.120 |
Why?
|
| Fish Oils | 1 | 2017 | 470 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 14722 | 0.120 |
Why?
|
| Choroid | 1 | 2015 | 322 | 0.110 |
Why?
|
| P-Selectin | 1 | 2016 | 600 | 0.110 |
Why?
|
| Vitreous Hemorrhage | 1 | 1993 | 48 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 10943 | 0.110 |
Why?
|
| Biocompatible Materials | 2 | 2019 | 1736 | 0.110 |
Why?
|
| Reference Values | 3 | 2016 | 4982 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 903 | 0.110 |
Why?
|
| Chemokine CCL4 | 2 | 2005 | 128 | 0.110 |
Why?
|
| Immunoprecipitation | 2 | 2017 | 905 | 0.110 |
Why?
|
| Galectin 3 | 1 | 2015 | 227 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 19905 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 867 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 644 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2019 | 2618 | 0.110 |
Why?
|
| NF-kappa B | 2 | 2015 | 2499 | 0.110 |
Why?
|
| Sugar Phosphates | 1 | 2012 | 41 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 720 | 0.110 |
Why?
|
| Receptors, Muscarinic | 1 | 2013 | 156 | 0.110 |
Why?
|
| Ophthalmic Artery | 1 | 2013 | 60 | 0.110 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2016 | 280 | 0.110 |
Why?
|
| Down-Regulation | 3 | 2009 | 3002 | 0.110 |
Why?
|
| Organ Size | 1 | 2017 | 2252 | 0.110 |
Why?
|
| Prostaglandin D2 | 1 | 2012 | 122 | 0.110 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2012 | 96 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2016 | 598 | 0.100 |
Why?
|
| Chemotaxis | 1 | 2015 | 607 | 0.100 |
Why?
|
| Iris | 2 | 2004 | 239 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2017 | 810 | 0.100 |
Why?
|
| Injections, Intraocular | 1 | 2011 | 30 | 0.100 |
Why?
|
| Myopia | 1 | 1994 | 254 | 0.100 |
Why?
|
| Disaccharides | 1 | 2012 | 171 | 0.100 |
Why?
|
| Kinetics | 2 | 2019 | 6473 | 0.100 |
Why?
|
| Prednisone | 1 | 2016 | 1574 | 0.100 |
Why?
|
| Receptors, Androgen | 4 | 2002 | 1058 | 0.100 |
Why?
|
| Japan | 3 | 2021 | 1360 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 4560 | 0.100 |
Why?
|
| Trigeminal Ganglion | 1 | 2012 | 186 | 0.100 |
Why?
|
| Efferent Pathways | 1 | 2012 | 167 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2012 | 165 | 0.100 |
Why?
|
| Pain | 1 | 2007 | 4986 | 0.100 |
Why?
|
| Epoprostenol | 1 | 2012 | 254 | 0.100 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2012 | 141 | 0.100 |
Why?
|
| Gamma Rays | 1 | 2012 | 320 | 0.100 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 9734 | 0.100 |
Why?
|
| Mannose-Binding Lectins | 1 | 2011 | 100 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 1996 | 506 | 0.100 |
Why?
|
| Angiogenic Proteins | 1 | 2011 | 104 | 0.100 |
Why?
|
| Blood | 1 | 2013 | 598 | 0.100 |
Why?
|
| Fibrosis | 1 | 2018 | 2029 | 0.100 |
Why?
|
| Afferent Pathways | 1 | 2012 | 302 | 0.100 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2011 | 225 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 15076 | 0.090 |
Why?
|
| Injections | 2 | 2007 | 840 | 0.090 |
Why?
|
| Disease | 1 | 2016 | 680 | 0.090 |
Why?
|
| Orbit | 1 | 1994 | 426 | 0.090 |
Why?
|
| Umbilical Veins | 1 | 2011 | 433 | 0.090 |
Why?
|
| Gene Silencing | 2 | 2007 | 1538 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2020 | 1859 | 0.090 |
Why?
|
| Photography | 1 | 2013 | 520 | 0.090 |
Why?
|
| Surface Plasmon Resonance | 1 | 2011 | 274 | 0.090 |
Why?
|
| Regeneration | 1 | 2019 | 1485 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 537 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 1994 | 691 | 0.090 |
Why?
|
| Postmenopause | 4 | 2002 | 2461 | 0.090 |
Why?
|
| Clodronic Acid | 1 | 2009 | 60 | 0.090 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 1061 | 0.090 |
Why?
|
| Dinoprostone | 1 | 2012 | 600 | 0.090 |
Why?
|
| Nerve Regeneration | 1 | 2015 | 788 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2016 | 3396 | 0.090 |
Why?
|
| Military Personnel | 1 | 2018 | 1133 | 0.090 |
Why?
|
| Etoposide | 1 | 2011 | 641 | 0.090 |
Why?
|
| History, 21st Century | 2 | 2007 | 1534 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2017 | 6365 | 0.090 |
Why?
|
| Dogs | 2 | 2004 | 3912 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 3336 | 0.090 |
Why?
|
| ROC Curve | 1 | 2017 | 3527 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 9239 | 0.080 |
Why?
|
| Tubulin | 1 | 2013 | 695 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1995 | 794 | 0.080 |
Why?
|
| Rural Health | 1 | 1990 | 305 | 0.080 |
Why?
|
| Logistic Models | 3 | 2019 | 13408 | 0.080 |
Why?
|
| Stereotaxic Techniques | 1 | 2011 | 536 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2019 | 1182 | 0.080 |
Why?
|
| Sodium Hydroxide | 3 | 2017 | 44 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 644 | 0.080 |
Why?
|
| Single-Blind Method | 4 | 2015 | 1590 | 0.080 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2009 | 145 | 0.080 |
Why?
|
| Nerve Fibers | 2 | 2010 | 687 | 0.080 |
Why?
|
| Child, Preschool | 8 | 2019 | 41006 | 0.080 |
Why?
|
| Cell Separation | 2 | 2014 | 1751 | 0.080 |
Why?
|
| Sensation | 1 | 2010 | 336 | 0.080 |
Why?
|
| Vision, Low | 1 | 1990 | 168 | 0.080 |
Why?
|
| Glycoconjugates | 1 | 2008 | 87 | 0.080 |
Why?
|
| Antigen Presentation | 3 | 2003 | 1284 | 0.080 |
Why?
|
| Rats | 7 | 2021 | 24260 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2020 | 23338 | 0.080 |
Why?
|
| Parasympathetic Nervous System | 1 | 2009 | 141 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2018 | 6459 | 0.080 |
Why?
|
| Stromal Cells | 2 | 2019 | 1355 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 261 | 0.080 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2007 | 59 | 0.080 |
Why?
|
| Retreatment | 1 | 2009 | 610 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 1598 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2503 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2012 | 1539 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2002 | 712 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 3508 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 685 | 0.080 |
Why?
|
| Progesterone | 2 | 2002 | 776 | 0.070 |
Why?
|
| Acanthamoeba | 1 | 2007 | 13 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 1097 | 0.070 |
Why?
|
| Antidepressive Agents | 2 | 2017 | 2838 | 0.070 |
Why?
|
| Nitriles | 1 | 2012 | 956 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 2505 | 0.070 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2007 | 75 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 2011 | 1663 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 906 | 0.070 |
Why?
|
| Suture Techniques | 3 | 1997 | 798 | 0.070 |
Why?
|
| Health Status | 1 | 2020 | 4034 | 0.070 |
Why?
|
| Estrogens | 3 | 2002 | 1566 | 0.070 |
Why?
|
| Macrophage-1 Antigen | 1 | 2007 | 290 | 0.070 |
Why?
|
| Prognosis | 6 | 2020 | 29063 | 0.070 |
Why?
|
| Antiprotozoal Agents | 2 | 2015 | 86 | 0.070 |
Why?
|
| Microcirculation | 1 | 2011 | 1286 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 2046 | 0.070 |
Why?
|
| Endothelium | 1 | 2009 | 778 | 0.070 |
Why?
|
| Random Allocation | 2 | 2001 | 2429 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2017 | 357 | 0.070 |
Why?
|
| Chemokines, CC | 1 | 2007 | 291 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2216 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 707 | 0.070 |
Why?
|
| Multivariate Analysis | 5 | 2003 | 12245 | 0.070 |
Why?
|
| Sympathetic Nervous System | 1 | 2009 | 514 | 0.070 |
Why?
|
| Liposomes | 1 | 2009 | 759 | 0.070 |
Why?
|
| Arteries | 1 | 2011 | 1119 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 1224 | 0.070 |
Why?
|
| Suppuration | 1 | 2005 | 56 | 0.070 |
Why?
|
| Skin | 2 | 2013 | 4364 | 0.070 |
Why?
|
| Chemokine CCL3 | 1 | 2005 | 83 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 547 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 13815 | 0.070 |
Why?
|
| Leukemic Infiltration | 1 | 2005 | 48 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2727 | 0.060 |
Why?
|
| Skin Transplantation | 2 | 2009 | 1074 | 0.060 |
Why?
|
| Air | 1 | 2005 | 182 | 0.060 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2007 | 306 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 1369 | 0.060 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2002 | 62 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 12959 | 0.060 |
Why?
|
| Defective Viruses | 1 | 2004 | 112 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2011 | 3144 | 0.060 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2005 | 226 | 0.060 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2005 | 227 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2009 | 1117 | 0.060 |
Why?
|
| Comorbidity | 1 | 2018 | 10388 | 0.060 |
Why?
|
| Histocompatibility Antigens | 2 | 2009 | 471 | 0.060 |
Why?
|
| Sclera | 2 | 1995 | 200 | 0.060 |
Why?
|
| MMPI | 1 | 1983 | 86 | 0.060 |
Why?
|
| Receptors, Notch | 1 | 2008 | 739 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 758 | 0.060 |
Why?
|
| Child | 9 | 2019 | 77709 | 0.060 |
Why?
|
| Risk | 1 | 2016 | 9687 | 0.060 |
Why?
|
| Pregnancy | 2 | 2023 | 29144 | 0.060 |
Why?
|
| Prosthesis Implantation | 2 | 2016 | 642 | 0.060 |
Why?
|
| Sex Factors | 1 | 2017 | 10397 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2009 | 942 | 0.060 |
Why?
|
| Androgen Antagonists | 4 | 2002 | 1377 | 0.060 |
Why?
|
| Neuropilin-2 | 1 | 2003 | 54 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2012 | 1572 | 0.060 |
Why?
|
| Thrombospondins | 1 | 2004 | 197 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2017 | 8949 | 0.060 |
Why?
|
| Schizophrenia, Paranoid | 1 | 1983 | 104 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2018 | 7729 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 5181 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 4042 | 0.060 |
Why?
|
| Splenectomy | 2 | 2002 | 395 | 0.050 |
Why?
|
| Caspases | 1 | 2006 | 928 | 0.050 |
Why?
|
| Societies, Scientific | 1 | 2004 | 220 | 0.050 |
Why?
|
| Psychometrics | 3 | 2016 | 3002 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 2866 | 0.050 |
Why?
|
| Macaca | 1 | 2004 | 440 | 0.050 |
Why?
|
| Wettability | 1 | 2002 | 24 | 0.050 |
Why?
|
| Phospholipids | 1 | 2006 | 784 | 0.050 |
Why?
|
| Florida | 1 | 2004 | 435 | 0.050 |
Why?
|
| Chemistry, Physical | 1 | 2002 | 156 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 2559 | 0.050 |
Why?
|
| Retinitis | 1 | 2002 | 35 | 0.050 |
Why?
|
| Decision Making | 1 | 2016 | 3887 | 0.050 |
Why?
|
| Rupture | 2 | 2002 | 433 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 773 | 0.050 |
Why?
|
| Chemical Phenomena | 1 | 2002 | 518 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Cadaver | 2 | 2017 | 1337 | 0.050 |
Why?
|
| Wisconsin | 1 | 2002 | 124 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 1 | 2005 | 534 | 0.050 |
Why?
|
| Desiccation | 1 | 2002 | 70 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2009 | 4479 | 0.050 |
Why?
|
| Health Occupations | 1 | 2003 | 224 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 475 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 3505 | 0.050 |
Why?
|
| Health Status Indicators | 2 | 2006 | 969 | 0.050 |
Why?
|
| Ciliary Body | 1 | 2002 | 173 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2004 | 377 | 0.050 |
Why?
|
| Neoplasms | 3 | 2020 | 21683 | 0.050 |
Why?
|
| Maryland | 1 | 2002 | 276 | 0.050 |
Why?
|
| Nuclease Protection Assays | 1 | 2000 | 16 | 0.050 |
Why?
|
| Neuroprotective Agents | 2 | 2018 | 941 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2017 | 2557 | 0.050 |
Why?
|
| Women's Health | 3 | 2007 | 2034 | 0.050 |
Why?
|
| Boston | 1 | 2013 | 9313 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2007 | 1951 | 0.050 |
Why?
|
| Neck | 2 | 2002 | 697 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2018 | 2104 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 2 | 2017 | 770 | 0.040 |
Why?
|
| Mice, Inbred A | 1 | 1999 | 248 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 323 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2002 | 370 | 0.040 |
Why?
|
| Orchiectomy | 2 | 1999 | 474 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 1152 | 0.040 |
Why?
|
| Infant | 6 | 2016 | 35136 | 0.040 |
Why?
|
| Lasers | 1 | 2004 | 952 | 0.040 |
Why?
|
| Gene Library | 1 | 2002 | 1074 | 0.040 |
Why?
|
| Feminization | 1 | 1999 | 23 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 13102 | 0.040 |
Why?
|
| Lead | 1 | 2004 | 852 | 0.040 |
Why?
|
| Hypophysectomy | 1 | 1999 | 113 | 0.040 |
Why?
|
| Awards and Prizes | 1 | 2004 | 375 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2006 | 1312 | 0.040 |
Why?
|
| Software | 1 | 2013 | 4443 | 0.040 |
Why?
|
| Solubility | 1 | 2000 | 1085 | 0.040 |
Why?
|
| Vitamin E | 1 | 2003 | 869 | 0.040 |
Why?
|
| Temperature | 1 | 2005 | 2206 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2002 | 2050 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 1999 | 298 | 0.040 |
Why?
|
| Australia | 1 | 2002 | 1170 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2024 | 40561 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2020 | 477 | 0.040 |
Why?
|
| Acute Disease | 3 | 2011 | 7149 | 0.040 |
Why?
|
| Nandrolone | 1 | 1998 | 17 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 211 | 0.040 |
Why?
|
| Commerce | 1 | 2023 | 592 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 1999 | 291 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 1999 | 422 | 0.040 |
Why?
|
| Myocardium | 1 | 2011 | 4776 | 0.040 |
Why?
|
| Uvea | 1 | 2017 | 31 | 0.040 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2018 | 95 | 0.040 |
Why?
|
| Algorithms | 2 | 2019 | 13881 | 0.040 |
Why?
|
| Alkalies | 1 | 2017 | 52 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 968 | 0.040 |
Why?
|
| Tetrahydrocortisol | 1 | 1996 | 1 | 0.040 |
Why?
|
| Biopsy | 2 | 2023 | 6756 | 0.040 |
Why?
|
| Bandages | 1 | 2019 | 266 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 1999 | 617 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2012 | 8554 | 0.040 |
Why?
|
| Astigmatism | 1 | 1997 | 69 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2002 | 1364 | 0.040 |
Why?
|
| Ovariectomy | 1 | 1999 | 661 | 0.040 |
Why?
|
| Neutrophils | 1 | 2009 | 3719 | 0.040 |
Why?
|
| Diclofenac | 1 | 1996 | 71 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2005 | 1344 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1999 | 659 | 0.030 |
Why?
|
| Registries | 2 | 2022 | 8089 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 6171 | 0.030 |
Why?
|
| Safety | 1 | 2001 | 1186 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2012 | 7880 | 0.030 |
Why?
|
| Dacryocystorhinostomy | 1 | 2016 | 72 | 0.030 |
Why?
|
| Prednisolone | 1 | 1996 | 334 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2019 | 694 | 0.030 |
Why?
|
| Odds Ratio | 3 | 2020 | 9849 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2124 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 1866 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2021 | 710 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 7913 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.030 |
Why?
|
| Spleen | 1 | 2001 | 2362 | 0.030 |
Why?
|
| Ultraviolet Rays | 2 | 1990 | 1060 | 0.030 |
Why?
|
| Stage-Specific Embryonic Antigens | 1 | 2014 | 6 | 0.030 |
Why?
|
| Forecasting | 1 | 2004 | 2951 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 8301 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2006 | 361 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2002 | 2585 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2001 | 1198 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 1983 | 1786 | 0.030 |
Why?
|
| Transducers, Pressure | 1 | 1994 | 56 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 7279 | 0.030 |
Why?
|
| Ectoderm | 1 | 2014 | 137 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2019 | 1959 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2020 | 2225 | 0.030 |
Why?
|
| Keratinocytes | 1 | 1998 | 798 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 977 | 0.030 |
Why?
|
| Amblyopia | 1 | 1995 | 143 | 0.030 |
Why?
|
| Keratin-3 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 1219 | 0.030 |
Why?
|
| Light | 1 | 2019 | 1374 | 0.030 |
Why?
|
| Recurrence | 2 | 2011 | 8340 | 0.030 |
Why?
|
| Cyclooxygenase 1 | 1 | 2012 | 104 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 1801 | 0.030 |
Why?
|
| Lung | 1 | 2011 | 9856 | 0.030 |
Why?
|
| Allergens | 1 | 1999 | 1320 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 356 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 109 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 1451 | 0.030 |
Why?
|
| Galectins | 1 | 2015 | 268 | 0.030 |
Why?
|
| Mast Cells | 1 | 1999 | 1544 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2019 | 1053 | 0.030 |
Why?
|
| Sheep | 1 | 1994 | 1437 | 0.030 |
Why?
|
| Fatty Acids | 3 | 2006 | 1809 | 0.030 |
Why?
|
| Vitreous Body | 1 | 1993 | 389 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 1375 | 0.020 |
Why?
|
| Lipocalins | 1 | 2012 | 170 | 0.020 |
Why?
|
| Testosterone | 1 | 2002 | 2420 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 290 | 0.020 |
Why?
|
| Aspirin | 1 | 2003 | 3282 | 0.020 |
Why?
|
| Cell Shape | 1 | 2012 | 375 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 2274 | 0.020 |
Why?
|
| Amnion | 1 | 2012 | 209 | 0.020 |
Why?
|
| Dermis | 1 | 2012 | 207 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2021 | 2948 | 0.020 |
Why?
|
| Kentucky | 1 | 1990 | 83 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 1983 | 2538 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2012 | 1101 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 2 | 2011 | 743 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2004 | 4234 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 1422 | 0.020 |
Why?
|
| Cell Size | 1 | 2012 | 643 | 0.020 |
Why?
|
| Age of Onset | 1 | 1997 | 3271 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2014 | 729 | 0.020 |
Why?
|
| Mutation | 2 | 2024 | 29786 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2015 | 1124 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2005 | 1588 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 611 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2021 | 2531 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1889 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1998 | 2740 | 0.020 |
Why?
|
| Virus Activation | 1 | 2011 | 319 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2016 | 1486 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 624 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2015 | 1463 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1990 | 876 | 0.020 |
Why?
|
| Imidazoles | 1 | 2015 | 1206 | 0.020 |
Why?
|
| Research Design | 1 | 2004 | 5987 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2002 | 3209 | 0.020 |
Why?
|
| Nervous System | 1 | 2011 | 554 | 0.020 |
Why?
|
| Corneal Topography | 1 | 2007 | 69 | 0.020 |
Why?
|
| Diet | 2 | 2003 | 7939 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 1999 | 3778 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2011 | 1035 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 3920 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 1992 | 1206 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 795 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2018 | 3712 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1157 | 0.020 |
Why?
|
| Phagocytes | 1 | 2008 | 297 | 0.020 |
Why?
|
| Destrin | 1 | 2005 | 9 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1708 | 0.020 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2005 | 43 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 523 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 2504 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2008 | 927 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 276 | 0.020 |
Why?
|
| Bacteria | 1 | 1995 | 2114 | 0.020 |
Why?
|
| Body Burden | 1 | 2004 | 158 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 11524 | 0.020 |
Why?
|
| Brain | 1 | 2011 | 26385 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 1994 | 2050 | 0.010 |
Why?
|
| Proteins | 1 | 2019 | 6103 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 2004 | 334 | 0.010 |
Why?
|
| Endothelium, Lymphatic | 1 | 2003 | 58 | 0.010 |
Why?
|
| Macular Degeneration | 1 | 1990 | 980 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 1678 | 0.010 |
Why?
|
| Growth Substances | 1 | 2005 | 784 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 2004 | 301 | 0.010 |
Why?
|
| Iron, Dietary | 1 | 2003 | 141 | 0.010 |
Why?
|
| Mucin 5AC | 1 | 2002 | 93 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 1990 | 1210 | 0.010 |
Why?
|
| Laser Coagulation | 1 | 2003 | 326 | 0.010 |
Why?
|
| Lipids | 2 | 2002 | 3305 | 0.010 |
Why?
|
| Vitamin B 6 | 1 | 2002 | 237 | 0.010 |
Why?
|
| Depression | 1 | 2020 | 7766 | 0.010 |
Why?
|
| Viscosity | 1 | 2000 | 328 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 1730 | 0.010 |
Why?
|
| Germany | 1 | 2002 | 862 | 0.010 |
Why?
|
| Calcium, Dietary | 1 | 2003 | 526 | 0.010 |
Why?
|
| Chickens | 1 | 2002 | 865 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2003 | 15165 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 3703 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 1095 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2971 | 0.010 |
Why?
|
| Vitamin A | 1 | 2003 | 615 | 0.010 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 9438 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2003 | 1901 | 0.010 |
Why?
|
| Zinc | 1 | 2003 | 684 | 0.010 |
Why?
|
| Nerve Net | 1 | 2010 | 2174 | 0.010 |
Why?
|
| Interleukins | 1 | 2003 | 791 | 0.010 |
Why?
|
| Insurance, Health | 1 | 1990 | 2494 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 2892 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 1460 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 2418 | 0.010 |
Why?
|
| Models, Biological | 1 | 2014 | 9583 | 0.010 |
Why?
|
| Complement C3 | 1 | 1999 | 461 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1990 | 7785 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 745 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 9959 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 1261 | 0.010 |
Why?
|
| Allergy and Immunology | 1 | 1997 | 169 | 0.010 |
Why?
|
| Refraction, Ocular | 1 | 1997 | 182 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 1995 | 128 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2002 | 2203 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 25625 | 0.010 |
Why?
|
| Cefazolin | 1 | 1995 | 96 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2001 | 1366 | 0.010 |
Why?
|
| Reflex, Pupillary | 1 | 1994 | 61 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 2020 | 0.010 |
Why?
|
| Gentamicins | 1 | 1995 | 255 | 0.010 |
Why?
|
| Cephalosporins | 1 | 1995 | 204 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 1995 | 277 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2004 | 2575 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2002 | 2017 | 0.010 |
Why?
|
| Culture Media | 1 | 1995 | 908 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 1990 | 5137 | 0.010 |
Why?
|
| Health Personnel | 1 | 2007 | 3218 | 0.010 |
Why?
|
| Autoantigens | 1 | 1997 | 892 | 0.010 |
Why?
|
| Proteomics | 1 | 2006 | 3638 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12797 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 3188 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1997 | 1821 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1995 | 1877 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2002 | 5097 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 18111 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2002 | 3297 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1989 | 964 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1997 | 3176 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1999 | 12354 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 7722 | 0.000 |
Why?
|
| Age Factors | 1 | 1999 | 18370 | 0.000 |
Why?
|